Does WellCare Cover Eliquis?

How WellCare Formularies Classify Eliquis

WellCare assigns every covered drug to a formulary tier that determines your out-of-pocket cost. Eliquis appears on most WellCare Medicare Advantage Prescription Drug (MAPD) and standalone Part D plan formularies, though the specific tier varies by plan year and geographic region. On the majority of WellCare plans, Eliquis sits at Tier 3 (preferred brand) or Tier 4 (non-preferred brand).

Tier placement matters. A Tier 3 copay might range from $35 to $47 per 30-day supply, while Tier 4 placement could push your share to $80 to $100 or more, depending on whether the plan charges a flat copay or percentage-based coinsurance. WellCare updates its formulary at least annually, and mid-year changes can occur with 30 days' written notice under CMS formulary change notification rules. The ARISTOTLE trial (N=18,201) established apixaban 5 mg twice daily as superior to warfarin for stroke prevention in atrial fibrillation, with a 21% relative risk reduction in stroke or systemic embolism and 31% reduction in major bleeding [1]. That efficacy profile is one reason most Part D plans maintain formulary access despite the drug's cost.

You should always verify your plan's current formulary on the Medicare Plan Finder or by calling the number on the back of your WellCare member ID card. Formulary documents are also available on WellCare's member portal.

Prior Authorization and Step Therapy Requirements

Some WellCare plans require prior authorization (PA) before they will cover Eliquis at the formulary copay. PA is more common on WellCare Medicaid managed care plans than on Medicare Advantage plans, but it can apply to either.

A PA request typically asks the prescriber to confirm the diagnosis (nonvalvular atrial fibrillation, venous thromboembolism, or post-surgical DVT prophylaxis), document that the patient has no contraindications, and verify appropriate dosing. The American Heart Association/American College of Cardiology 2019 AFib guideline recommends DOACs over warfarin for most patients with nonvalvular atrial fibrillation who are eligible for anticoagulation [2]. Citing this guideline in the PA letter can expedite approval.

Step therapy is less common for Eliquis on WellCare Medicare plans because CMS limits step therapy for Part D drugs in the anticoagulant class. On WellCare Medicaid plans in certain states, you may need to try warfarin first and document clinical failure or intolerance before Eliquis is approved. If your PA is denied, you have the right to request an exception or appeal through WellCare's coverage determination process, which must be resolved within 72 hours for a standard request or 24 hours for an expedited request under CMS Part D appeals rules.

What Eliquis Costs on a WellCare Medicare Plan

Your actual cost for Eliquis on a WellCare plan depends on three variables: the formulary tier, your plan's benefit phase, and whether you receive Low-Income Subsidy (Extra Help).

During the initial coverage phase (after you meet your deductible), a Tier 3 copay on a typical WellCare MAPD plan runs $40 to $47 for a 30-day supply. Tier 4 coinsurance might be 33% to 40% of the negotiated price. Because Eliquis carries a retail price near $600 per month, that coinsurance can exceed $150 before any additional discounts apply.

The Inflation Reduction Act capped total annual out-of-pocket Part D spending at $2,000 starting in 2025, which significantly benefits patients taking high-cost brand drugs like Eliquis [3]. Once you reach the $2,000 cap, you pay nothing for the remainder of the plan year. WellCare also participates in the Medicare Prescription Payment Plan, allowing you to spread your out-of-pocket costs across monthly installments rather than paying the full copay at the pharmacy counter.

For WellCare members who qualify for Extra Help (Low-Income Subsidy), copays drop to $4.50 for brand-name drugs in 2026. That makes Eliquis dramatically more affordable. You can check eligibility for Extra Help through the Social Security Administration.

WellCare Medicaid Plans and Eliquis

WellCare operates Medicaid managed care plans in more than a dozen states. Medicaid formularies (called Preferred Drug Lists or PDLs) are state-specific, so Eliquis coverage rules differ depending on where you live.

In many states, Eliquis is on the Medicaid PDL but requires prior authorization confirming that warfarin is not appropriate. States like Florida, Georgia, Kentucky, and Texas have historically included DOACs on their PDLs with PA requirements [4]. A few states place Eliquis on a non-preferred tier, meaning higher cost-sharing or a mandatory generic-first step. Because apixaban does not yet have a generic equivalent approved by the FDA (as of May 2026), the "generic-first" step effectively requires a trial of warfarin or, in some cases, a different DOAC such as rivaroxaban.

Medicaid copays are generally capped at nominal amounts ($1 to $3 per prescription in most states), so the out-of-pocket cost for Eliquis on WellCare Medicaid is minimal once coverage is approved. The challenge is getting through the PA process. Your prescriber should include the specific clinical rationale. The AMPLIFY trial (N=5,395) demonstrated that apixaban was noninferior to standard enoxaparin/warfarin therapy for acute VTE treatment while causing 56% less major bleeding [5]. Including trial data like this strengthens a PA submission.

How Eliquis Compares to Other Anticoagulants on WellCare Formularies

WellCare plans typically cover multiple anticoagulant options. Understanding how Eliquis stacks up against alternatives on your plan can help you and your prescriber choose the most clinically appropriate and affordable option.

Warfarin is the least expensive choice. It costs $4 to $15 per month as a generic and sits on Tier 1 or Tier 2 of virtually every WellCare formulary. But warfarin requires regular INR monitoring, has extensive food and drug interactions, and carries higher intracranial hemorrhage risk compared to DOACs [1].

Xarelto (rivaroxaban) often occupies the same tier as Eliquis on WellCare plans. Some WellCare formularies place one DOAC on a preferred tier and the other on non-preferred, creating a cost differential. If your plan prefers rivaroxaban, switching could save $30 to $60 per month. The ROCKET AF trial (N=14,264) showed rivaroxaban was noninferior to warfarin for stroke prevention in AFib [6]. A head-to-head comparison is not available from a randomized trial, though a meta-analysis published in The Lancet suggested apixaban may have a modest bleeding advantage over rivaroxaban [7].

Savaysa (edoxaban) and Pradaxa (dabigatran) are also covered on some WellCare formularies. Dabigatran has the advantage of a specific reversal agent (idarucizumab), while apixaban and rivaroxaban are reversed by andexanet alfa. Tier placement for these alternatives varies. Check your plan's formulary or call WellCare member services.

How to Get Eliquis Covered if Your WellCare Plan Denies It

A coverage denial does not mean you are out of options. Several pathways exist to obtain Eliquis through your WellCare plan or at reduced cost outside the plan.

The first step after a denial is a coverage determination request (for Medicare) or a PA appeal (for Medicaid). Your prescriber submits a letter explaining why Eliquis is medically necessary and why alternatives are not appropriate. Common clinical reasons include warfarin instability (time in therapeutic range <65%), history of intracranial hemorrhage on warfarin, inability to attend regular INR monitoring, or significant drug-drug interactions with warfarin. The 2023 ACC/AHA atrial fibrillation guideline update gives DOACs a Class I recommendation over warfarin for eligible patients [8].

If the appeal is denied, Medicare Part D members can request an Independent Review Entity (IRE) review. This external review is binding on the plan.

Outside the plan, the Bristol-Myers Squibb/Pfizer Eliquis 360 Support program offers a copay card for commercially insured patients (not valid for Medicare, Medicaid, or other federal programs). For Medicare patients, BMS offers a patient assistance program that may provide Eliquis at no cost to those who meet income requirements. Details are available at the manufacturer's patient support website.

Clinical Evidence Supporting Eliquis Use

Understanding why your doctor prescribed Eliquis (rather than a cheaper alternative) can help you advocate for coverage during the PA or appeals process.

Apixaban has one of the strongest evidence bases among the DOACs. The ARISTOTLE trial demonstrated superiority over warfarin for stroke prevention in nonvalvular AFib, with a 1.27% per year rate of stroke or systemic embolism versus 1.60% for warfarin (hazard ratio 0.79, 95% CI 0.66 to 0.95, P=0.01) [1]. Major bleeding occurred at 2.13% per year with apixaban versus 3.09% with warfarin (HR 0.69, P<0.001) [1]. All-cause mortality was also lower with apixaban (3.52% vs. 3.94%, HR 0.89, P=0.047).

For venous thromboembolism, the AMPLIFY trial showed apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily was noninferior to conventional therapy (enoxaparin followed by warfarin) for recurrent VTE, with a major bleeding rate of 0.6% versus 1.8% [5].

Dr. Christopher Granger, a principal investigator of the ARISTOTLE trial, stated: "Apixaban demonstrated consistent benefits across a wide range of patient subgroups, including the elderly and those with renal impairment, which is particularly relevant for real-world prescribing decisions" [9].

The American College of Chest Physicians (ACCP) 2021 VTE guideline recommends DOACs over warfarin for VTE treatment in patients without cancer or antiphospholipid syndrome [10]. Having your physician cite these specific guidelines and trial results in PA paperwork increases approval likelihood.

Pharmacy Options That Can Lower Your Eliquis Cost on WellCare

Where you fill your prescription affects what you pay. WellCare plans designate preferred and non-preferred pharmacies, and filling at a preferred pharmacy can reduce your copay by 20% to 40%.

Mail-order pharmacy is another cost-reduction tool. WellCare's mail-order benefit typically offers a 90-day supply for the cost of two monthly copays. For a drug like Eliquis with a $45 monthly copay, that means paying $90 for three months instead of $135. WellCare's preferred mail-order pharmacy information is listed in your Evidence of Coverage document.

Some WellCare plans also participate in pharmacy discount programs or have agreements with specific retail chains. CVS, Walgreens, and Walmart are common preferred pharmacy partners, but this varies by plan and region. Filling at a non-preferred pharmacy can add $5 to $20 per fill to your cost.

90-day retail fills at preferred pharmacies (where available) offer similar savings to mail order while maintaining the convenience of in-person pickup. Ask your pharmacist or WellCare member services whether your plan supports 90-day retail fills for Eliquis.

A 2022 analysis published in the Journal of the American Heart Association found that out-of-pocket costs were a significant predictor of DOAC adherence, with patients paying more than $50 per month showing 23% lower adherence rates compared to those paying under $10 [11]. Reducing your copay is not just a financial decision. It directly affects whether you take the medication consistently enough to prevent stroke.

Switching Between WellCare Plans for Better Eliquis Coverage

If your current WellCare plan places Eliquis on a high-cost tier, you may find better coverage by switching to a different WellCare plan during the Annual Enrollment Period (October 15 through December 7). WellCare offers multiple MAPD and Part D plans in most service areas, and formulary placement of Eliquis can differ between plans from the same insurer.

Use the Medicare Plan Finder tool to compare Eliquis costs across all available WellCare plans in your ZIP code. Enter apixaban and your dosage to see estimated annual drug costs, including premium, deductible, and copay/coinsurance for each plan.

You may also qualify for a Special Enrollment Period (SEP) if you experience certain life events: moving to a new service area, losing other drug coverage, qualifying for Extra Help, or entering a nursing facility [12]. During an SEP, you can switch to any available plan in your area.

The 2024 CMS Star Ratings showed that WellCare's Part D plans averaged 3.0 to 3.5 stars depending on the contract, with drug pricing and formulary breadth being key quality metrics that CMS evaluates [12]. Choosing a higher-rated WellCare plan may indicate better pharmacy benefit management, including more favorable DOAC coverage.